A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia

Psychological Medicine

Volumn 30, Issue 1, 2000, Pages 95-105

  Copolov, David L ^a   Link, C G G ^b   Kowalcyk, B ^b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PROLACTIN; QUETIAPINE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SOMNOLENCE; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0033974433     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0033291799001476     Document Type: Article

References (31)

1. Arvanitis, L. A., Miller, B. G. & the Seroquel Trial 13 Study Group (1997). Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry 42, 233-246.
2. Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., Hamilton, S. & the Olanzapine HGAD Study Group (1996). Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14, 111-123.
3. Borison, R. L., Arvanitis, L. A., Miller, B. G. & the US Seroquel Study Group (1996). ICI 204,636, an atypical antipsycholic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. Journal of Clinical Psychopharmacology 16, 158-169.
4. Casey, D. E. (1989). Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99, S47-S53.
5. Chiodo, L. A. & Bunney, B. S. (1983). Typical and atypical antipsychotics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Neuroscience 3, 1607-1619.
6. Chouinard, G., Jones, B., Remington, G., Bloom, D., Addington, D., MacEwan, W., Labelle, A., Beauclair, L. & Arnott, W. (1993). A Canadian, multi-centre, placebo-controlled trial of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology 13, 25-40.
7. Fabre, L. F. (1993). A multicentre open pilot trial of ICI 204,636 in hospitalised patients with acute psychotic symptomatology. Schizophrenia Research 9, 237(Abs).
8. Fabre, L. F., Arvanitis, L., Pultz, J., Jones, V. M., Malick, J. B. & Slotnick, M. D. (1995). ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clinical Therapeutics 17, 366-378.
9. Ghadirian, A. M., Chouinard, G. & Annable, L. (1982) Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. Journal of Nervous and Mental Disease 170, 463-467.
10. Goldstein, J. M., Litwin, L. C., Sutton, E. B. & Malick, J. B. (1993). Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacolgy 112, 293-298.
11. Guy, W. (1976). AIMS: Abnormal Involuntary Movement Scale. In ECDEU Assessment Manual for Psychopharmacology (ed. W. Guy, revised edition). US Department of Health. Education and Welfare: Washington, DC.
12. Guy, W. & Bonato, R. (1970). CGI: Clinical Global Impressions: Manual for the ECDEU Assessment Battery 2 Revised Edition. National Institute of Mental Health: Maryland
13. Halbreich, U. & Palter, S. (1996). Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophrenia Bulletin 22, 447-454.
14. Hirsch, S. R. & Barnes T. R. E. (1995). The clinical treatment of schizophrenia with antipsychotic medicine. In Schizophrenia (ed. S. R. Hirsch, D. R. Weinberger), pp. 443-468. Blackwell Science Ltd. UK: Oxford.
15. Hirsch, S. R., Link, C. G. G., Goldstein, J. M. & Arvanitis, L. A. (1996). ICI 204,636, a new atypical antipsychotic drug. British Journal of Psychiatry 168(suppl. 29), 45-56.
16. Kay, S., Fiszbein, A. & Opler, L. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
17. Marder, S. R. & Meibach, R. C. (1994). Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 151, 825-835.
18. Marken, P. A., Haykal, R. F. & Fisher, J. N. (1992). Management of psychotropic-induced hyperprolactinaemia. Clinical Pharmacology 11, 851-856.
19. Meats, P. (1997). Quetiapine ('Seroquel'): an effective and well tolerated atypical antipsychotic. International Journal of Psychiatry in Clinical Practice 1, 231-239.
20. Meltzer, H. (1992). The importance of serotonin-dopamine interactions in the action of clozapine. British Journal of Psychiatry 160, 22-29.
21. Migler, B. M., Warawa, E. J. & Malick, J. B. (1993). Seroquel: behavioural effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 112, 299-307.
22. Peuskens, J. & Link, C. G. G. (1997). A comparison of ICI 204,636 and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica 96, 265-273.
23. Richardson M. A., Haughland G. & Craig, T. J. (1991). Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. American Journal of Psychiatry 148, 1322-1328.
24. Saller, C. F. & Salama, A. I. (1993). Seroquel: biochemical profile of a potential atypical antipsychotic Psychopharmacology 112, 285-292.
25. Simpson, G. M. & Angus, J. W. S. (1970). A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica 212, 11-19.
26. Small, J. G., Hirsch, S. R., Arvanitis, L. A., Miller, B. G., Link, C. G. G. & the Seroquel Study Group (1997). Quetiapine in patients with schizophrema. A high-and low-dose double-blind comparison with placebo. Archives of General Psychiatry 54, 549-557.
27. Sullivan, G. & Lukoff, D. (1990). Sexual side-effects of antipsychotic medication: evaluation and interventions. Hospital Community Psychiatry 11, 1238-1241.
28. Tollefson, G. D., Beasley, C. M., Tran, P. V., Street, J. S., Kreuger, J. A., Tamura, R. N., Graffeo, K. A. & Thieme, M. E. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international and collaborative trial. American Journal of Psychiatry 154, 457-465.
29. Van Putten, T. (1974). Why do schizophrenic patients fail to take their drugs? Archives of General Psychiatry 31, 67-72.
30. White, F. J. & Wang, R. Y. (1983). Differential aspects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221, 1054-1057.
31. Zelaschi, N. M., Delucchi, G. A. & Rodriguez, J. L. (1996). High plasma prolactin levels after long-term neuroleptic treatment. Biological Psychiatry 39, 900-901.